Autopsy report · NCT01023880
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Cause of deathNo reason given
Life of this trial
- Registered 1 month before it started.
- Ran for about 3 years before it stopped.
- 62 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Cephalon
- Sponsor type
- Industry
- Conditions
- Multiple Myeloma
- Interventions
- CEP-18770
- Participants
- 62
- Sites
- 13
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.